Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant plus ondansetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients
2014-001783-34Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in chemotherapy-induced nausea and vomiting (CINV) comparing Fosaprepitant plus ondansetron with Placebo plus ondansetron (2 arms). Primary endpoint: Complete Response in delayed phase. Started Jun 2015; status: completed.
02
Drugs
fosaprepitantondansetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2014-001783-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001783-34.